BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
18 déc. 2024 09h00 HE
|
BioAge Labs, Inc.
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to...
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
06 déc. 2024 16h35 HE
|
BioAge Labs, Inc.
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated...
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
05 déc. 2024 16h30 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs to Present at Upcoming Investor Conferences
21 nov. 2024 16h30 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
BioAge Labs Reports Third Quarter 2024 Financial Results and Provides Business Updates
07 nov. 2024 16h30 HE
|
BioAge Labs, Inc.
Initiated Phase 2 STRIDES trial of azelaprag in combination with tirzepatide for obesity Completed $238.3 million initial public offering and concurrent private placement, cash and cash equivalents...
BioAge Labs to Present Preclinical Data for APJ Agonist Azelaprag at ObesityWeek 2024
04 nov. 2024 09h00 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as...
BioAge Labs to Present at Jefferies London Healthcare Conference
24 oct. 2024 09h00 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases...
BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement
01 oct. 2024 16h30 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...
BioAge Labs Announces Pricing of Upsized Initial Public Offering
25 sept. 2024 20h00 HE
|
BioAge Labs, Inc.
RICHMOND, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic...
BioAge Raises $90M to Treat Aging and Age-related Diseases
03 déc. 2020 08h00 HE
|
BioAge Labs, Inc.
Proceeds will support advancement of the company’s pipeline and proprietary platform for identifying and developing therapies to treat diseases of aging Company announces Chief Medical Officer as it...